New drug aims to soothe severe agitation in kids with mental health conditions
Symptom relief
Recruiting now
This study tests an experimental medicine called BXCL501 to see if it can safely reduce sudden severe agitation in children aged 10-17 with schizophrenia or bipolar disorder. About 140 participants will receive either the drug or a placebo. The goal is to quickly calm symptoms li…
Phase: PHASE1 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated May 11, 2026 20:53 UTC